Market Cap 21.85M
Revenue (ttm) 1.20M
Net Income (ttm) -22.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,891.67%
Debt to Equity Ratio 0.05
Volume 293,400
Avg Vol 269,626
Day's Range N/A - N/A
Shares Out 31.15M
Stochastic %K 82%
Beta -0.35
Analysts Strong Sell
Price Target $7.15

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
janlukas
janlukas Aug. 3 at 12:49 PM
$LGVN Today, an agricultural products company, hyfm, rose over 500% in pre-market trading because of good news about its platform. I wonder what a biotech can do with explosive news? My model remains Drug, which went from under $1.X to over $100 in a few days.
0 · Reply
PeterJPL
PeterJPL Aug. 2 at 7:17 PM
🧭 5 Swing Trades to Watch — August 3–7 Ratings measure weekly setup quality, not predicted upside. $SOUN — 4.88/5 – Q2 earnings Aug. 5 after close. Watching revenue growth, enterprise adoption, margins, backlog and guidance. $LGVN — 4.79/5 – ELPIS II Phase 2b topline data expected during August. Strong clinical catalyst, but no exact release date. $QBTS — 4.74/5 – Q2 earnings Aug. 6 before market open. Best direct quantum setup; watch bookings, commercial adoption and cash burn. $RGTI — 4.68/5 – Q2 earnings Aug. 6 after close. Clean quantum catalyst, with sympathy likely tied to the earlier $QBTS reaction. $REPL — 4.63/5 – FDA-decision reaction setup for RP1. Once the outcome is known, this becomes a gap/reaction trade rather than a normal run-up. Event-driven watchlist only. Confirmation and risk control still matter.
0 · Reply
Hosai
Hosai Jul. 31 at 4:13 PM
$LGVN Have to take with pinch of salt but I asked chat gpt to do a valuation of this company, it looked at in quite a lot of depth and various different aspects including all filings etc. It gives me a base case fair value today of $5.50 a share. That's not after positive news or anything that's today with the potentials of various different outcomes from Aug readout weighed up. Not sure if I'm missing anything but seems like quite an a-symetrical risk/reward here going into the results?
0 · Reply
poilu
poilu Jul. 31 at 2:15 PM
$LGVN So they've met compliance.....great. What's their long term plan? Are all bets on the Phase 2a CLEAR-MIND tests being successful?
1 · Reply
johnrivers0110
johnrivers0110 Jul. 30 at 4:09 PM
$LGVN 🩸🔺 gooooood now I can short
0 · Reply
johnrivers0110
johnrivers0110 Jul. 30 at 2:37 AM
$LGVN 🩸🩸🩸🩸🩸🩸🩸🔺
0 · Reply
focafoca99
focafoca99 Jul. 29 at 8:17 PM
$LGVN elected three new board members and reconstituted its audit committee to meet Nasdaq rules.
0 · Reply
Southshd
Southshd Jul. 29 at 5:31 PM
$LGVN Added today! 200k shares total! Gl felow bulls!
0 · Reply
Mangust05
Mangust05 Jul. 25 at 8:08 AM
$LGVN this stock behavior nuke power . Let’s do $300 and I do retirement 🚀🥷🏌️🏇🥊🔥🙌🙏🦅
0 · Reply
janlukas
janlukas Jul. 24 at 10:07 AM
$LGVN In my opinion, the meeting to discuss RS has been canceled. Everyone can draw their own conclusions. If Elpis is positive, LGVN is worth at least $1.X billion, which translates to about $80 per share.
1 · Reply
Latest News on LGVN
Longeveron appoints Marie Washburn CFO

2026-07-06T20:10:28.000Z - 4 weeks ago

Longeveron appoints Marie Washburn CFO


Longeveron Transcript: AGM 2026

Jul 1, 2026, 11:00 AM EDT - 4 weeks ago

Longeveron Transcript: AGM 2026


Longeveron granted SME status by European Medicines Agency

2026-06-09T13:29:08.000Z - 2 months ago

Longeveron granted SME status by European Medicines Agency


Longeveron to Present at BIO International Convention 2026

Jun 4, 2026, 9:15 AM EDT - 2 months ago

Longeveron to Present at BIO International Convention 2026


Longeveron Proxy statement: Proxy filing

May 20, 2026, 8:00 AM EDT - 2 months ago

Longeveron Proxy statement: Proxy filing


Longeveron Proxy statement: Proxy filing

May 20, 2026, 8:00 AM EDT - 2 months ago

Longeveron Proxy statement: Proxy filing


Longeveron reports Q1 EPS (19c) vs. (34c) last year

2026-05-13T21:35:38.000Z - 2 months ago

Longeveron reports Q1 EPS (19c) vs. (34c) last year


Longeveron Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Longeveron Earnings Call Transcript: Q1 2026


Longeveron Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Longeveron Quarterly report: Q1 2026


Longeveron Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Longeveron Earnings release: Q1 2026


Longeveron Slides: Investor presentation

May 13, 2026, 7:00 AM EDT - 2 months ago

Longeveron Slides: Investor presentation


Longeveron downgraded to Hold from Buy at Maxim

2026-05-11T15:43:29.000Z - 3 months ago

Longeveron downgraded to Hold from Buy at Maxim


Longeveron Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 3 months ago

Longeveron Proxy statement: Proxy filing


Longeveron Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 3 months ago

Longeveron Slides: Investor presentation


Longeveron Registration statement: Registration filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Longeveron Registration statement: Registration filing


Longeveron granted Chinese patent for potency assay methods

2026-04-08T13:38:32.000Z - 4 months ago

Longeveron granted Chinese patent for potency assay methods


Longeveron granted Chinese patent for potency assay methods

2026-04-08T13:27:11.000Z - 4 months ago

Longeveron granted Chinese patent for potency assay methods


Longeveron Slides: Investor presentation

Apr 1, 2026, 7:00 AM EDT - 4 months ago

Longeveron Slides: Investor presentation


Longeveron price target lowered to $2 from $3 at Roth Capital

2026-03-18T23:20:16.000Z - 4 months ago

Longeveron price target lowered to $2 from $3 at Roth Capital


Longeveron Earnings Call Transcript: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Longeveron Earnings Call Transcript: Q4 2025


Longeveron Earnings release: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Longeveron Earnings release: Q4 2025


Longeveron Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Longeveron Annual report: Q4 2025


Longeveron Slides: Investor presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

Longeveron Slides: Investor presentation


3 Penny Stocks to Watch Now, 3/11/26

2026-03-11T14:11:00.000Z - 5 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC INKT


Longeveron prices 6.01M shares at 52c in private placement

2026-03-10T13:16:09.000Z - 5 months ago

Longeveron prices 6.01M shares at 52c in private placement


Longeveron Proxy statement: Proxy Filing

Mar 3, 2026, 7:00 AM EST - 5 months ago

Longeveron Proxy statement: Proxy Filing


Longeveron names Stephen Willard as CEO, succeeding Than Powell

2026-02-13T21:35:23.000Z - 6 months ago

Longeveron names Stephen Willard as CEO, succeeding Than Powell


Longeveron Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Longeveron Earnings Call Transcript: Q3 2025


Longeveron Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Longeveron Earnings release: Q3 2025


Longeveron Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Longeveron Quarterly report: Q3 2025


Longeveron Slides: Corporate Presentation

Nov 4, 2025, 4:00 PM EST - 9 months ago

Longeveron Slides: Corporate Presentation


Longeveron® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 11 months ago

Longeveron® Announces Key Leadership Updates


Longeveron Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings Call Transcript: Q2 2025


Longeveron Earnings release: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings release: Q2 2025


Longeveron Quarterly report: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 1 year ago

Longeveron Quarterly report: Q2 2025


Longeveron Slides: Investor Presentation

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Longeveron Slides: Investor Presentation


Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 1 year ago

Longeveron Announces Up To $17.5 Million Public Offering


Longeveron Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Longeveron Registration statement: Registration Filing


Longeveron Registration statement: Registration Filing

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Longeveron Registration statement: Registration Filing


Longeveron® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 1 year ago

Longeveron® Appoints Than Powell as Chief Business Officer


Longeveron Transcript: AGM 2025

Jun 13, 2025, 1:00 PM EDT - 1 year ago

Longeveron Transcript: AGM 2025


Longeveron® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 1 year ago

Longeveron® to Attend BIO International Convention 2025


Longeveron Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings Call Transcript: Q1 2025


Longeveron Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings release: Q1 2025


Longeveron Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Quarterly report: Q1 2025


Longeveron Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Slides: Q1 2025


Longeveron Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Proxy statement: Proxy Filing


Longeveron Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Proxy statement: Proxy Filing


Longeveron Registration statement: Registration Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Registration statement: Registration Filing


Longeveron Transcript: 37th Annual ROTH Conference

Mar 18, 2025, 12:00 PM EDT - 1 year ago

Longeveron Transcript: 37th Annual ROTH Conference


Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 1 year ago

Longeveron® to Present at the 37th Annual Roth Conference


Longeveron Earnings Call Transcript: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Earnings Call Transcript: Q4 2024


Longeveron Earnings release: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Earnings release: Q4 2024


Longeveron Annual report: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Annual report: Q4 2024


Longeveron Slides: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Slides: Q4 2024


Longeveron Transcript: Emerging Growth Conference 79

Feb 19, 2025, 3:10 PM EST - 1 year ago

Longeveron Transcript: Emerging Growth Conference 79


Longeveron Transcript: Biotech Showcase 2025

Jan 14, 2025, 7:00 PM EST - 1 year ago

Longeveron Transcript: Biotech Showcase 2025


Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025


Longeveron Transcript: Emerging Growth Conference77

Dec 5, 2024, 12:00 PM EST - 1 year ago

Longeveron Transcript: Emerging Growth Conference77


Longeveron Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Earnings Call Transcript: Q3 2024


Longeveron Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Quarterly report: Q3 2024


Longeveron Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Earnings release: Q3 2024


janlukas
janlukas Aug. 3 at 12:49 PM
$LGVN Today, an agricultural products company, hyfm, rose over 500% in pre-market trading because of good news about its platform. I wonder what a biotech can do with explosive news? My model remains Drug, which went from under $1.X to over $100 in a few days.
0 · Reply
PeterJPL
PeterJPL Aug. 2 at 7:17 PM
🧭 5 Swing Trades to Watch — August 3–7 Ratings measure weekly setup quality, not predicted upside. $SOUN — 4.88/5 – Q2 earnings Aug. 5 after close. Watching revenue growth, enterprise adoption, margins, backlog and guidance. $LGVN — 4.79/5 – ELPIS II Phase 2b topline data expected during August. Strong clinical catalyst, but no exact release date. $QBTS — 4.74/5 – Q2 earnings Aug. 6 before market open. Best direct quantum setup; watch bookings, commercial adoption and cash burn. $RGTI — 4.68/5 – Q2 earnings Aug. 6 after close. Clean quantum catalyst, with sympathy likely tied to the earlier $QBTS reaction. $REPL — 4.63/5 – FDA-decision reaction setup for RP1. Once the outcome is known, this becomes a gap/reaction trade rather than a normal run-up. Event-driven watchlist only. Confirmation and risk control still matter.
0 · Reply
Hosai
Hosai Jul. 31 at 4:13 PM
$LGVN Have to take with pinch of salt but I asked chat gpt to do a valuation of this company, it looked at in quite a lot of depth and various different aspects including all filings etc. It gives me a base case fair value today of $5.50 a share. That's not after positive news or anything that's today with the potentials of various different outcomes from Aug readout weighed up. Not sure if I'm missing anything but seems like quite an a-symetrical risk/reward here going into the results?
0 · Reply
poilu
poilu Jul. 31 at 2:15 PM
$LGVN So they've met compliance.....great. What's their long term plan? Are all bets on the Phase 2a CLEAR-MIND tests being successful?
1 · Reply
johnrivers0110
johnrivers0110 Jul. 30 at 4:09 PM
$LGVN 🩸🔺 gooooood now I can short
0 · Reply
johnrivers0110
johnrivers0110 Jul. 30 at 2:37 AM
$LGVN 🩸🩸🩸🩸🩸🩸🩸🔺
0 · Reply
focafoca99
focafoca99 Jul. 29 at 8:17 PM
$LGVN elected three new board members and reconstituted its audit committee to meet Nasdaq rules.
0 · Reply
Southshd
Southshd Jul. 29 at 5:31 PM
$LGVN Added today! 200k shares total! Gl felow bulls!
0 · Reply
Mangust05
Mangust05 Jul. 25 at 8:08 AM
$LGVN this stock behavior nuke power . Let’s do $300 and I do retirement 🚀🥷🏌️🏇🥊🔥🙌🙏🦅
0 · Reply
janlukas
janlukas Jul. 24 at 10:07 AM
$LGVN In my opinion, the meeting to discuss RS has been canceled. Everyone can draw their own conclusions. If Elpis is positive, LGVN is worth at least $1.X billion, which translates to about $80 per share.
1 · Reply
poilu
poilu Jul. 20 at 2:04 PM
$LGVN Isn't this ticker going to face compliance issues soon? I'm surprised this hasn't been delisted completely or dropped to OTC yet.
3 · Reply
janlukas
janlukas Jul. 15 at 12:26 PM
$LGVN Now the jtai stock is almost +900% in pre-market, Lgvn if the data are positive from Elpis possible spike to $80 only cure in the world for children. The $80 is not said by me but by specialized sites.
2 · Reply
Aawilliam2003
Aawilliam2003 Jul. 15 at 2:10 AM
$LGVN what is the value of the Aug readout? Since it’s only 12 months endpoint, that seems way to early for any real efficacy read. Even it it’s positive it does t mean much. Anyone disagree?
1 · Reply
Going4Blood
Going4Blood Jul. 14 at 9:33 PM
$LGVN When your company can't turn a profit, but the CEO just takes a pay raise increasing to half a million . . .
1 · Reply
Mangust05
Mangust05 Jul. 14 at 2:23 PM
$LGVN everything possible here . Imagine if they get approved. Could fly over $300🚀🚀🚀🥷
0 · Reply
gr8whitenorth
gr8whitenorth Jul. 14 at 4:54 AM
$LGVN the good ol days 🦍🚀🌚
0 · Reply
Dorps332
Dorps332 Jul. 13 at 3:19 PM
$LGVN doesn’t seem like the market cares about this stock anymore. Even with decent data it can’t move it
1 · Reply
WILLWISH
WILLWISH Jul. 12 at 7:15 PM
$LGVN The company has received Rare Pediatric Disease and Orphan Drug designations for key programs, which can provide regulatory advantages..
1 · Reply
Orlandotrader
Orlandotrader Jul. 11 at 1:53 PM
$LGVN The Data Good!!! The Regulatory not Good. Another15 Million will be collected after Success. This will take them into Esrly 2027. New FDA meeting to Agree on Primary EndPoint. Will FDA Request phase 3 Trial? Most probable. Will need to find a Financial Backer.
1 · Reply
focafoca99
focafoca99 Jul. 8 at 8:21 PM
$LGVN granted special equity awards to its Executive Chairman for his role in the March 2026 financing transaction.
1 · Reply
Huskersnsaints
Huskersnsaints Jul. 7 at 2:36 PM
$LGVN Well evidently they are going to dilute this into a reverse split nothing else makes sense absolutely no upward movement No updates just share price erosion and at the same time reverse splits are most of these type of stocks business model as shareholders are the last concern to the companies management!!!!!!
1 · Reply
Kings124566
Kings124566 Jul. 7 at 3:16 AM
$LGVN explode or implode?
0 · Reply